Human Organoids Market worth $1,901 million by 2025 - Exclusive Report by MarketsandMarkets™

 The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%, according to a new report by MarketsandMarkets™. Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

Browse in-depth TOC on "Human Organoids Market”
143 – Tables
23 – Figures
174 – Pages

The human organoids market includes major Tier I and II suppliers like BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Demand for human organoids from key end-users has declined  a bit amidst the global COVID-19 pandemic. Industry experts believe that COVID-19 will have short-term decline in the growth for the human organoids market in 2020, but will experience normal growth as the market gradually steadies by the end of 2020.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Demand for liver transplants result in the segment occupying the high share of the human orgnaoids market

Liver segment owes a good market share in Human Orgnaoids market. The large share of this segment is attributed to factors such as the advancements in technology among researchers and academia (coupled with growing industry-academia collaborations for organoids research, rising numbers of liver transplants and the investments by the both private and public players in the market.

Kidney estimated to be the growing market

The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures),  and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.

Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

Browse Adjacent Market: Biotechnology Market Research Reports & Consulting

Related Reports:

3D Bioprinting Market by Component (3D Bioprinters (Microextrusion, Inkjet, Laser, Magnetic), Bioink (Natural, Synthetic, Hybrid)), Material(Hydrogel, Living Cells), Application (Research, Clinical), End user (Biopharma, Academia) - Global Forecast to 2027
https://www.marketsandmarkets.com/Market-Reports/3d-bioprinting-market-170201787.html

Global Human Organoids Market is Expecting to Grow at a Steady Rate During Forecast Period (2020-2025)

 Major Objectives Behind This Study:

# To define, describe, and forecast the global Human Organoids Market on the basis of product, usability, application, end user, and region.

# To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).

# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.

# To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders.

# To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.

# To profile the key market players and comprehensively analyze their market shares and core competencies.

# To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global human organoids market.

Expected Revenue Gains During Forecast Period:

The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Growth Influencing Factors:

The global human organoids market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of transplants, and increased funding and public-private investments are key factors driving the growth of the human organoids market.

Opportunity: Increasing focus on drug discovery activities

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.

A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.

Recent Developments in the Global Human Organoids Market:

# In 2020, BIOIVT (US) partnered with upcyte technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).

# In 2019, Hurel and Cyprotex came into partnership which enabled Cyprotex to independently validate the HµREL multi-donor co­culture model for clearance studies.

# In 2019, Organovo collaborated with MCRI and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatment for kidney diseases.

# In 2018, Absolute Antibody merged with Kerafast to increase access to unique reagents.

Challenge: Dearth of skilled professionals

Skilled professionals, such as researchers and technicians, are required to set up and run experiments involving organoids, and further make observations, obtain results, and analyze the obtained data. The lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses and increase the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for interpretation, method development, validation, operation, and troubleshooting activities.

Delelopmental biology is the largest application segment of the human orgnaoids market

Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Human Organoids Market - Major Revenue Gains are Expected by 2025

 Major Growth Boosting Factors:

Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids market.

Expected Growth in Revenue Generation:

The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%.

Overview:

The study involved four major activities to estimate the current size of the human organoids market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Demand for liver transplants result in the segment occupying the high share of the human orgnaoids market

Liver segment owes a good market share in Human Orgnaoids market. The large share of this segment is attributed to factors such as the advancements in technology among researchers and academia (coupled with growing industry-academia collaborations for organoids research, rising numbers of liver transplants and the investments by the both private and public players in the market.

Kidney estimated to be the growing market

The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures), and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.

Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.

Leading Companies Operating in the Global Market:

Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Human Organoids Market worth $1,901 million by 2025

 Global Revenue Growth:

The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %. Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

By product, liver segment is expected to have the largest market share during the forecast period

The large share of this segment is attributed to factors such as the significant adoption of new technologies  among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of 3D bioprinting  and the increased number of liver tranplants and diseases.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Delelopmental biology is the largest application segment of the human orgnaoids market

Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms.

Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.

Pharmaceuticals & Biotechnology companies accounted for the largest share of the human organoids market, by end users, in 2020

Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements.

Technical and regulatory challenges related to the development of new drug molecules create complexities for pharmaceutical and biotechnology companies in terms of time and cost. However, due to strict regulations, companies often produce technologically superior products with better safety norms.

North America is the largest regional market for Human Organoids

North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers. Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.

Key Market Players:

BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

BioIVT founded in 1981 and is headquartered in New York, US. The company is a leading global provider of biological specimens, including human tissues, cell products, blood, and other biofluids. The company provides a wide range of services, ranging from target and biomarker validation, phenotypic assays to characterize novel therapeutics, and clinical assay development to in vitro hepatic modeling solutions. It is a supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Some of the major end users of the company’s products are research organizations, pharmaceutical and biotechnological companies, medical device companies, and academic research institutes. BioIVT offers its products and services across North America, the Asia Pacific, Europe, and the Middle East & Africa. The company has two distributors in the Asia Pacific region, namely, Veritas Corporation (Japan) and Research Institute for Liver Diseases (Shanghai) Co., Ltd. (China).

Human Organoids Market worth $1,901 million by 2025

Overview:

The study involved four major activities to estimate the current size of the human organoids market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.

Growth Boosting Factors:

The global human organoids market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of transplants, and increased funding and public-private investments are key factors driving the growth of the human organoids market.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Research Methodologies Followed:

Primary Research:

The human organoids market comprises several stakeholders such as  Manufacturers of human organoid products, Healthcare service providers, Manufacturers of pharmaceutical products, Pharmaceutical and biotechnology companies, Clinical research organizations (CROs), Clinical testing laboratories, Public and private research organizations, Research laboratories and academic institutes, Market research and consulting firms The demand side of this market is characterized by the increasing incidence of transplants and technological advancements, and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Secondary Research:

In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the orthopedic braces and supports market study.

Opportunity: Increasing focus on drug discovery activities

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.

A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.

Challenge: Dearth of skilled professionals

Skilled professionals, such as researchers and technicians, are required to set up and run experiments involving organoids, and further make observations, obtain results, and analyze the obtained data. The lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses and increase the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for interpretation, method development, validation, operation, and troubleshooting activities.

According to the US Bureau of Labor Statistics, the US economy faces a shortage of STEM (science, technology, engineering, and mathematics) professionals. As per the US Bureau of Labor Statistics, there is a dearth of skilled professionals in the fields of medical research, pharmaceuticals, and sciences. Several European countries, which are among the early adopters of new technologies in the life sciences sector, are facing similar challenges due to the shortage of graduates in STEM fields. Similarly, in India, the shortage of skilled talent in the STEM sector has increased from 6% in January 2014 to 12% in January 2018. This is considered a major challenge in the organoids market.

Kidney estimated to be the growing market

The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures),  and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.

Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Global Leading Companies:

Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

Human Organoids Market worth $1,901 million by 2025

 Overview:

The study involved four major activities to estimate the current size of the human organoids market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Revenue Growth Dynamics:

The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %.

Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

Demand for liver transplants result in the segment occupying the high share of the human orgnaoids market

Liver segment owes a good market share in Human Orgnaoids market. The large share of this segment is attributed to factors such as the advancements in technology among researchers and academia (coupled with growing industry-academia collaborations for organoids research, rising numbers of liver transplants and the investments by the both private and public players in the market.

Kidney estimated to be the growing market

The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures),  and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.

Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Key Players:

Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).